Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Boehringer Ingelheim
Medtronic
Merck
Johnson and Johnson

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AZD3293

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug AZD3293: Patents, clinical trial progress, indications

AZD3293 is an investigational drug.

There have been 15 clinical trials for AZD3293. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2017.

The most common disease conditions in clinical trials are Alzheimer Disease, Dementia, and [disabled in preview]. The leading clinical trial sponsors are AstraZeneca, Eli Lilly and Company, and Parexel.

There are five US patents protecting this investigational drug and sixty international patents.

Recent Clinical Trials for AZD3293
TitleSponsorPhase
A Study of LY3314814 in Early Alzheimer's Disease DementiaAstraZenecaPhase 3
A Study of LY3314814 in Early Alzheimer's Disease DementiaEli Lilly and CompanyPhase 3
A Study of LY3314814 in Healthy Participants When Taken With RosuvastatinAstraZenecaPhase 1

See all AZD3293 clinical trials

Clinical Trial Summary for AZD3293

Top disease conditions for AZD3293
Top clinical trial sponsors for AZD3293

See all AZD3293 clinical trials

US Patents for AZD3293

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD3293   Start Trial Compounds and their use as BACE inhibitors AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD3293   Start Trial Compounds and their use as BACE inhibitors AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD3293   Start Trial Compounds and their use as BACE inhibitors Astrazeneca AB (Sodertalje, SE)   Start Trial
AZD3293   Start Trial Compounds and their use as BACE inhibitors ASTRAZENECA AB (Sodertalje, SE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD3293

Drugname Country Document Number Estimated Expiration Related US Patent
AZD3293 Argentina 084553 2030-12-22   Start Trial
AZD3293 Argentina 107709 2030-12-22   Start Trial
AZD3293 Australia 2011345389 2030-12-22   Start Trial
AZD3293 Australia 2016200538 2030-12-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Harvard Business School
Mallinckrodt
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.